Published in Medical Letter on the CDC and FDA, July 11th, 2004
FDA's letter addresses two primary concerns. The first pertains to a cost comparison chart describing the daily cost of common anti-retroviral therapies. FDA raised concerns that this chart could be interpreted to imply that Norvir can be used as monotherapy at a sub-therapeutic dose.
Abbott developed this chart to respond to concerns regarding Abbott's re-pricing of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.